サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：肺機能検査の世界市場2023-2030
市場調査レポート
商品コード
1296934

肺機能検査の世界市場2023-2030

Global Pulmonary Function Testing Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 105 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
肺機能検査の世界市場2023-2030
出版日: 2023年05月29日
発行: Orion Market Research
ページ情報: 英文 105 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の肺機能検査市場は予測期間中にCAGR 8.3％で成長すると予測されます。世界の肺機能検査システム市場の需要は、肺関連疾患の発生率の上昇、肺機能検査システムの技術進歩、職業性肺疾患によって煽られています。例えば、2023年4月、Asan Medical Center（AMC）は、コンピュータ断層撮影（CT）検査結果に基づいて肺機能を90％以上の精度で予測する人工知能肺検査装置を開発しました。このアルゴリズムは、CTスキャンに基づいて肺機能が低下している患者を特定することができます。さらに、このAIは、強制換気量（FVC）と強制呼気1秒量（FEV1）の両方の測定値に基づいて、ハイリスク指標を約85％の精度で予測できることが判明しました。

さらに、公的機関や民間団体による資金提供の増加は、市場の成長をさらに促進すると思われます。2023年4月、Noah Medicalは、使い捨てプローブを使用してナビゲーション付き肺気管支内視鏡検査を実施するよう設計されたGalaxyシステムを支える商業用エンジンの構築を支援するため、1億5,000万米ドルを調達しました。Galaxyシステムのような次世代ロボットプラットフォームは、手技のギャップを埋め、より顧客のニーズに応える優れた臨床的価値を提供します。このシステムにはまた、NoahがTool-in-Lesion Tomo+テクノロジー（TiLT+）と呼んでいるものも装備されており、外科医にリアルタイムで画像ガイドによる最新情報を提供し、生検ツールが標的組織内に完全に入ったことを確認するのに役立ちます。

セグメント別の展望

サルコイドーシスセグメントが世界の肺機能検査市場で大きなシェアを占める

用途別では、サルコイドーシスセグメントが予測期間中に大きな成長を遂げると予測されています。サルコイドーシス疾患に関する認知度の向上と、規制機関による広範な資金提供は、市場成長にプラスの影響を与えます。例えば、2022年10月、Xentria社は、サルコイドーシスの実験的抗体療法であるXTMAB-16の開発を進めるために2,500万米ドルの資金を調達しました。この資金調達により、同社はXentriaのパイプラインを前進させ、必要としている患者のために重要な治療薬を開発するという目標に対して実行します。さらに、サルコイドーシス研究財団によると、2021年には米国で17万5,000人近くがサルコイドーシスに罹患しており、世界全体では120万人がサルコイドーシスに罹患していると推定されています。

地域別展望

北米地域が世界の肺機能検査市場で圧倒的な市場シェアを占める

地域別では、北米が予測期間で最も高いCAGRを示すと予測されます。診断における技術的進歩の高まり、整備された肺医療インフラ、慢性呼吸器疾患の有病率の増加が、市場成長を後押しする主な要因です。例えば、2022年9月、AI肺がん診断のイノベーターであるOptellumは、拡大を加速するために1,400万米ドルのシリーズA資金を確保しました。この世界初のプラットフォームは、医師がリスクのある患者を特定・追跡し、肺がんの兆候を早期に最適に診断することを支援するもので、腫瘍のある患者には早期に治療を開始でき、良性病変に対する生検などの侵襲的な処置を最小限に抑えることができます。

目次

第1章 レポートの概要

  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論
  • 規則と規制

第3章 競合情勢

  • 主要企業分析
    • Koninklijke Philips N.V.
    • ResMed Inc.
    • Thermo Fisher Scientific Inc.
  • 主要戦略分析

第4章 市場セグメンテーション

  • 肺機能検査の世界市場：デバイスタイプ別
    • ハンドヘルド
    • 卓上
  • 肺機能検査の世界市場：製品タイプ別
    • スパイロメトリー
    • 肺活量検査
    • 動脈血ガス検査
    • パルスオキシメトリー
    • その他
  • 肺機能検査の世界市場：用途別
    • 呼吸器感染症
    • 喘息
    • アスベスト症
    • 腫瘍
    • サルコイドーシス
    • その他
  • 肺機能検査の世界市場：エンドユーザー別
    • 病院
    • 臨床検査機関
    • 診断研究所

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Carestream Health.
  • Carestream Health.
  • Chest M.I., Inc.
  • Cosmed Srl
  • Ganshorn Medizin Electronic GmbH
  • Koko, Llc
  • Medical Electronic Corp.
  • Medical Equipment Europe GmbH
  • Mgc Diagnostics Corp.
  • Minato Medical Science Co.
  • Morgan Scientific Inc.
  • ndd Medical Technologies, Inc.
  • Omron Healthcare, Inc.
  • PulmOne USA Inc.
  • Vyaire Medical, Inc.
図表

LIST OF TABLES

  • 1. GLOBAL PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY DEVICE TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL HANDHELD PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL TABLETOP PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 5. GLOBAL PULMONARY SPIROMETRY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL PULMONARY LUNG VOLUME FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL PULMONARY ARTERIAL BLOOD GAS FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL PULSE OXIMETRY PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL OTHERS PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 11. GLOBAL PULMONARY FUNCTION TESTING FOR RESPIRATORY INFECTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL PULMONARY FUNCTION TESTING FOR ASTHMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL PULMONARY FUNCTION TESTING FOR ASBESTOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL PULMONARY FUNCTION TESTING FOR TUMORS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL PULMONARY FUNCTION TESTING FOR SARCOIDOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL PULMONARY FUNCTION TESTING FOR OTHERS (CHEST SURGERY) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 18. GLOBAL PULMONARY FUNCTION TESTING IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL PULMONARY FUNCTION TESTING IN CLINICAL LABORATRIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. GLOBAL PULMONARY FUNCTION TESTING IN DIAGNOSTICS LABORATRIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 21. GLOBAL PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY DEVICE TYPE, 2022-2030 ($ MILLION)
  • 24. NORTH AMERICAN PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 25. NORTH AMERICAN PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 26. NORTH AMERICAN PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 27. EUROPEAN PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 28. EUROPEAN PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY DEVICE TYPE, 2022-2030 ($ MILLION)
  • 29. EUROPEAN PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 30. EUROPEAN PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 31. EUROPEAN PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 32. ASIA-PACIFIC PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 33. ASIA-PACIFIC PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY DEVICE TYPE, 2022-2030 ($ MILLION)
  • 34. ASIA-PACIFIC PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE , 2022-2030 ($ MILLION)
  • 35. ASIA-PACIFIC PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 36. ASIA-PACIFIC PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 38. REST OF THE WORLD PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY DEVICE TYPE, 2022-2030 ($ MILLION)
  • 39. REST OF THE WORLD PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 40. REST OF THE WORLD PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 41. REST OF THE WORLD PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY DEVICE TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL HANDHELD PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL TABLETOP PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022 VS 2030 (%)
  • 5. GLOBAL PULMONARY SPIROMETRY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL PULMONARY LUNG VOLUME FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL PULMONARY ARTERIAL BLOOD GAS FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL PULSE OXIMETRY PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL OTHERS PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022 VS 2030 (%)
  • 11. GLOBAL PULMONARY FUNCTION TESTING FOR RESPIRATORY INFECTIONS MARKET RESEARCH AND ANALYSIS BY REGION,2022 VS 2030 (%)
  • 12. GLOBAL PULMONARY FUNCTION TESTING FOR ASTHMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL PULMONARY FUNCTION TESTING FOR ASBESTOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL PULMONARY FUNCTION TESTING FOR TUMORS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL PULMONARY FUNCTION TESTING FOR SARCOIDOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL PULMONARY FUNCTION TESTING FOR OTHERS (CHEST SURGERY) MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL PULMONARY FUNCTION TESTING MARKET RESEARCH AND ANALYSIS BY END USER, 2022 VS 2030 (%)
  • 18. GLOBAL PULMONARY FUNCTION TESTING IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 19. GLOBAL PULMONARY FUNCTION TESTING IN CLINICAL LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 20. GLOBAL PULMONARY FUNCTION TESTING IN DIAGNOSTICS LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 21. US PULMONARY FUNCTION TESTING MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. CANADA PULMONARY FUNCTION TESTING MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. UK PULMONARY FUNCTION TESTING MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. FRANCE PULMONARY FUNCTION TESTING MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. GERMANY PULMONARY FUNCTION TESTING MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. ITALY PULMONARY FUNCTION TESTING MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SPAIN PULMONARY FUNCTION TESTING MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. ROE PULMONARY FUNCTION TESTING MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. INDIA PULMONARY FUNCTION TESTING MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. CHINA PULMONARY FUNCTION TESTING MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. JAPAN PULMONARY FUNCTION TESTING MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC PULMONARY FUNCTION TESTING MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD PULMONARY FUNCTION TESTING MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027409

Title: Global Pulmonary Function Testing Market Size, Share & Trends Analysis Report by Device Type (Handheld, and Tabletop), by Product Type (Spirometry, Lung Volume Testing, Arterial Blood Gas Testing, Pulse Oximetry, and Others (Maximal Voluntary Ventilation)), by Application (Respiratory Infections, Asthma, Asbestosis, Tumors, Sarcoidosis, and Others (chest surgery), and by End User (Hospitals, Clinical Laboratories, and Diagnostics Laboratories) Forecast Period (2023-2030).

The global pulmonary function testing market is anticipated to grow at a CAGR of 8.3% during the forecast period. Global pulmonary function testing systems market demand is fueled by the rising incidence of lung-related disorders, technological advancements in pulmonary function testing systems and occupational lung diseases. For instance, in April 2023, Asan Medical Center (AMC) developed an artificial intelligence lung testing device that predicts lung function based on computed tomography (CT) test results with an accurate rate of 90% or higher. This algorithm is capable of identifying patients with decreased lung function based on CT scans. Moreover, the AI was found to predict the high-risk indicator based on both measurements forced vital capacity (FVC), and forced expiratory volume in one second (FEV1) with approximately 85% accuracy.

In addition, increasing funding by public and private organizations will further propel the market growth. In April 2023, Noah Medical raised $150 million to help build a commercial engine behind its Galaxy system, designed to perform navigated lung bronchoscopies using disposable probes. Next-generation robotics platforms such as Galaxy System are filling procedural gaps to provide superior clinical values to better serve customers' needs. The system is also equipped with what Noah has dubbed Tool-in-Lesion Tomo+ technology, or TiLT+, which provides surgeons with real-time, image-guided updates to help confirm when the biopsy tool is fully within its target tissue.

Segmental Outlook

The global pulmonary function testing market is segmented based on its device type, product type, application, and end user. Based on device type, the market is bifurcated into handheld, and tabletop. Based on product type, the market is categorized into spirometry, lung volume testing, arterial blood gas testing, pulse oximetry, and others. Based on application, the market is divided into respiratory infections, asthma, asbestosis, tumors, sarcoidosis, and others. Based on end user, the market is segmented into hospitals, clinical laboratories, and diagnostics laboratories. Based on product type, the spirometry segment holds a significant market share. Increasing the use of spirometry for detecting lung infection is driving the segment growth. Spirometry tells whether the patient has a breathing problem caused by an obstruction of air that's left in his or her lungs or a restriction of air entering the lung.

The Sarcoidosis Segment Holds a Significant Share in the Global Pulmonary Function Testing Market

Based on application, the sarcoidosis segment is projected to witness significant growth during the forecast period. An increase in awareness regarding sarcoidosis diseases, along with extensive funding provided by regulatory bodies positively influences the market growth. For instance, in October 2022, Xentria has raised $25 million in funding to further the development of XTMAB-16, its experimental antibody therapy for sarcoidosis. With this funding, the company advance the Xentria pipeline and execute against the goal of developing critical therapeutics for patients in need. Furthermore, according to the Foundation for Sarcoidosis Research, in 2021 nearly 175,000 people in the US have sarcoidosis, with an estimated 1.2 million individuals living with the disease globally.

Regional Outlooks

The global pulmonary function testing market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa and Latin America). The market can be analyzed for a particular region or country level as per the requirement. Among these, the Europe region is projected to hold a significant share in the pulmonary function testing market. A considerable increase in the incidence of chronic obstructive pulmonary diseases and asthma cases, along with numerous campaigns organized by regulatory bodies to create awareness among the people, drive the market growth.

Global Pulmonary Function Testing Market Growth, by Region 2023-2030

Source: OMR Analysis

The North America Region Holds a Prominent Market Share in the Global Pulmonary Function Testing Market

Based on region, North America is projected to have the highest CAGR over the forecast period. Rising technological advancements in diagnostics, well-developed pulmonary healthcare infrastructure, increasing prevalence of chronic respiratory diseases, are the primary factor that boost the market growth. For instance, in September 2022, Optellum, AI Lung Cancer diagnosis innovator, secures $14million Series A funding to accelerate expansion. This first-of-a-kind platform help physicians identify and track at-risk patients, and optimally diagnose the signs of lung cancer early, so treatment can be started sooner for patients with tumors, and invasive procedures such as biopsies on benign lesions can be minimized.

Market Players Outlook

The major companies serving the global pulmonary function testing market include Ganshorn Medizin Electronic GmbH, KoKo, LLC, Koninklijke Philips N.V., Medical Electronic Corp., NDD Medical Technologies, and others. The market players are considerably contributing to the market growth by the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2020, NDD Medical Technologies (ndd), introduced single patient-use, inline filters for its lung function testing devices in response to COVID-19. Ensuring added safety, the filters complement NDD's revolutionary, highly portable EasyOne spirometry range, including EasyOne Air, Pro, and Pro LAB. Ndd's popular spirometers are of the most sensitive devices, delivering reliable, real-time lung function results and enabling specialists diagnoses of chronic lung diseases, even at the point of care.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global pulmonary function testing market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Koninklijke Philips N.V.
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. ResMed Inc.
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Thermo Fisher Scientific Inc.
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Pulmonary Function Testing Market by Device Type
    • 4.1.1. Handheld
    • 4.1.2. Tabletop
  • 4.2. Global Pulmonary Function Testing Market by Product Type
    • 4.2.1. Spirometry
    • 4.2.2. Lung Volume Testing
    • 4.2.3. Arterial Blood Gas Testing
    • 4.2.4. Pulse Oximetey
    • 4.2.5. Others (Maximal Voluntary Ventilation)
  • 4.3. Global Pulmonary Function Testing Market by Application
    • 4.3.1. Respiratory Infections
    • 4.3.2. Asthma
    • 4.3.3. Asbestosis
    • 4.3.4. Tumors
    • 4.3.5. Sarcoidosis
    • 4.3.6. Others (Chest Surgery)
  • 4.4. Global Pulmonary Function Testing Market by End User
    • 4.4.1. Hospitals
    • 4.4.2. Clinical Laboratories
    • 4.4.3. Diagnostics Laboratories

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Carestream Health.
  • 6.2. Carestream Health.
  • 6.3. Chest M.I., Inc.
  • 6.4. Cosmed Srl
  • 6.5. Ganshorn Medizin Electronic GmbH
  • 6.6. Koko, Llc
  • 6.7. Medical Electronic Corp.
  • 6.8. Medical Equipment Europe GmbH
  • 6.9. Mgc Diagnostics Corp.
  • 6.10. Minato Medical Science Co.
  • 6.11. Morgan Scientific Inc.
  • 6.12. ndd Medical Technologies, Inc.
  • 6.13. Omron Healthcare, Inc.
  • 6.14. PulmOne USA Inc.
  • 6.15. Vyaire Medical, Inc.